ThromboGenics to Present at the Jefferies 2011 Global Life Sciences Conference in New York

LEUVEN, Belgium, June 7, 2011 -

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical
company focused on developing innovative ophthalmic medicines, announces that
Patrik De Haes, the Chief Executive Officer of ThromboGenics will present an
overview of the Company's strategy and key development programs at the
Jefferies 2011 Global Life Sciences Conference at the Grand Hyatt Hotel in
New York City, U.S. on 8 June 2011 at 8.30am EDT.

The Company's presentation can be accessed via
www.thrombogenics.com

AboutThromboGenics

ThromboGenics is a biopharmaceutical company focused on the
discovery and development of innovative ophthalmic medicines. The Company's
lead product ocriplasmin (microplasmin) has completed two Phase III clinical
trials for the pharmacological treatment of symptomatic vitreomacular
adhesion (sVMA). Ocriplasmin is also being evaluated in Phase II clinical
development for additional vitreoretinal conditions. ThromboGenics is also
developing novel antibody therapeutics in collaboration with BioInvent
International; these include TB-402 (anti-Factor VIII), a long-acting
anticoagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for cancer
in partnership with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company
is listed on NYSE Euronext Brussels under the symbol THR. More information is
available at www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered
"forward-looking". Such forward-looking statements are based on current
expectations, and, accordingly, entail and are influenced by various risks
and uncertainties. The Company therefore cannot provide any assurance that
such forward-looking statements will materialize and does not assume an
obligation to update or revise any forward-looking statement, whether as a
result of new information, future events or any other reason. Additional
information concerning risks and uncertainties affecting the business and
other factors that could cause actual results to differ materially from any
forward-looking statement is contained in the Company's Annual Report.

For further information please contact:

    ThromboGenics

    Dr. Patrik De Haes, CEO              Tel: +32-16-75-13-10
                                         patrik.dehaes@thrombogenics.com
    Chris Buyse, CFO                     Tel: +32-16-75-13-10
                                         chris.buyse@thrombogenics.com

    Citigate Dewe Rogerson

    David Dible/ Nina Enegren/ Sita Shah Tel: +44(0)207-638-95-71
                                         nina.enegren@citigatedr.co.uk

.